BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Clinical trial NCT04969861 · TERMINATED

Trial details

NCT number: NCT04969861
Sponsor: Nektar Therapeutics
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer

Start date: 2022-03-09
Primary completion: 2022-04-22
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.